Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumors 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × dalotuzumab × Clear all
NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Merck Sharp & Dohme LLC

Phase 1 Completed
20 enrolled 30 charts
Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
558 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡